Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KG-TM4SF1
- Development stage
- Preclinical
- Lead developer
- Beijing KeyGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
KG-TM4SF1 is a preclinical therapeutic candidate developed by Beijing KeyGen (KeyGen Biotech) for the treatment of various solid tumors. It targets Transmembrane 4 L6 family member 1 (TM4SF1), a cell-surface protein that is highly expressed in several types of cancer, including lung, breast, and colon cancers, as well as on tumor-associated vascular endothelial cells. TM4SF1 plays a critical role in cell migration, proliferation, and the formation of new blood vessels (angiogenesis) within the tumor microenvironment. The KG-TM4SF1 program includes both a standalone monoclonal antibody and an antibody-drug conjugate (ADC) format. The ADC is designed to utilize the specificity of the anti-TM4SF1 antibody to deliver a potent cytotoxic payload directly to cancer cells, thereby maximizing anti-tumor efficacy while minimizing off-target effects on healthy tissues.
- Other names
- TM4SF1-targeting monoclonal antibodyTM-4SF1-targeting monoclonal antibodyTM 4SF1-targeting monoclonal antibodyTM4SF1-ADCTM-4SF1-ADCTM 4SF1-ADC
02
Targets
TM4SF1 (Transmembrane 4 L6 family member 1)
Beyond the preview
Go deeper on KG-TM4SF1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KG-TM4SF1.